553 related articles for article (PubMed ID: 23294032)
1. Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy.
Markvardsen LH; Debost JC; Harbo T; Sindrup SH; Andersen H; Christiansen I; Otto M; Olsen NK; Lassen LL; Jakobsen J;
Eur J Neurol; 2013 May; 20(5):836-42. PubMed ID: 23294032
[TBL] [Abstract][Full Text] [Related]
2. Subcutaneous immunoglobulin preserves muscle strength in chronic inflammatory demyelinating polyneuropathy.
Markvardsen LH; Harbo T; Sindrup SH; Christiansen I; Andersen H; Jakobsen J;
Eur J Neurol; 2014 Dec; 21(12):1465-70. PubMed ID: 25041191
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study.
Markvardsen LH; Sindrup SH; Christiansen I; Olsen NK; Jakobsen J; Andersen H;
Eur J Neurol; 2017 Feb; 24(2):412-418. PubMed ID: 28000311
[TBL] [Abstract][Full Text] [Related]
4. Comparisons in fluctuation of muscle strength and function in patients with immune-mediated neuropathy treated with intravenous versus subcutaneous immunoglobulin.
Christiansen I; Markvardsen LH; Jakobsen J
Muscle Nerve; 2018 Apr; 57(4):610-614. PubMed ID: 28881389
[TBL] [Abstract][Full Text] [Related]
5. Long-term neurophysiological and clinical response in patients with chronic inflammatory demyelinating polyradiculoneuropathy treated with subcutaneous immunoglobulin.
Cirillo G; Todisco V; Tedeschi G
Clin Neurophysiol; 2018 May; 129(5):967-973. PubMed ID: 29554579
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
van Schaik IN; van Geloven N; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; Merkies IS;
Trials; 2016 Jul; 17(1):345. PubMed ID: 27455854
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous immunoglobulin therapy for multifocal motor neuropathy.
Eftimov F; Vermeulen M; de Haan RJ; van den Berg LH; van Schaik IN
J Peripher Nerv Syst; 2009 Jun; 14(2):93-100. PubMed ID: 19691531
[TBL] [Abstract][Full Text] [Related]
8. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy.
Latov N; Deng C; Dalakas MC; Bril V; Donofrio P; Hanna K; Hartung HP; Hughes RA; Merkies IS; van Doorn PA;
Arch Neurol; 2010 Jul; 67(7):802-7. PubMed ID: 20457948
[TBL] [Abstract][Full Text] [Related]
9. Improvement of hemoglobin levels after a switch from intravenous to subcutaneous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.
Markvardsen LH; Christiansen I; Jakobsen J
Transfusion; 2016 Oct; 56(10):2443-2448. PubMed ID: 27401495
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial.
van Schaik IN; Bril V; van Geloven N; Hartung HP; Lewis RA; Sobue G; Lawo JP; Praus M; Mielke O; Durn BL; Cornblath DR; Merkies ISJ;
Lancet Neurol; 2018 Jan; 17(1):35-46. PubMed ID: 29122523
[TBL] [Abstract][Full Text] [Related]
11. Long-term treatment with subcutaneous immunoglobulin in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a follow-up period up to 7 years.
Gentile L; Mazzeo A; Russo M; Arimatea I; Vita G; Toscano A
Sci Rep; 2020 May; 10(1):7910. PubMed ID: 32404895
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy.
Lee DH; Linker RA; Paulus W; Schneider-Gold C; Chan A; Gold R
Muscle Nerve; 2008 Mar; 37(3):406-9. PubMed ID: 17918749
[TBL] [Abstract][Full Text] [Related]
13. Vigorimeter grip strength in CIDP: a responsive tool that rapidly measures the effect of IVIG--the ICE study.
Vanhoutte EK; Latov N; Deng C; Hanna K; Hughes RA; Bril V; Dalakas MC; Donofrio P; van Doorn PA; Hartung HP; Merkies IS
Eur J Neurol; 2013 May; 20(5):748-55. PubMed ID: 22891893
[TBL] [Abstract][Full Text] [Related]
14. Acute motor response following a single IVIG treatment course in chronic inflammatory demyelinating polyneuropathy.
Harbo T; Andersen H; Jakobsen J
Muscle Nerve; 2009 Apr; 39(4):439-47. PubMed ID: 19229876
[TBL] [Abstract][Full Text] [Related]
15. Quality of life in chronic inflammatory demyelinating polyneuropathy patients treated with subcutaneous immunoglobulin.
Ryltoft AK; Al-Zuhairy A; Sindrup SH; Andersen H; Markvardsen LK
Acta Neurol Scand; 2020 Dec; 142(6):637-640. PubMed ID: 33404110
[TBL] [Abstract][Full Text] [Related]
16. [Subcutaneous immunoglobulin. Treatment in chronic inflammatory demyelinating polyradiculo-neuropathy].
Nogués MA; Varela FJ; Seminario G; Insúa MC; Bezrodnik L
Medicina (B Aires); 2016; 76(1):36-9. PubMed ID: 26826992
[TBL] [Abstract][Full Text] [Related]
17. Long-term therapy with high doses of subcutaneous immunoglobulin in multifocal motor neuropathy.
Harbo T; Andersen H; Jakobsen J
Neurology; 2010 Oct; 75(15):1377-80. PubMed ID: 20938030
[TBL] [Abstract][Full Text] [Related]
18. Diffusion tensor imaging can be used to detect lesions in peripheral nerves in patients with chronic inflammatory demyelinating polyneuropathy treated with subcutaneous immunoglobulin.
Markvardsen LH; Vaeggemose M; Ringgaard S; Andersen H
Neuroradiology; 2016 Aug; 58(8):745-52. PubMed ID: 27114080
[TBL] [Abstract][Full Text] [Related]
19. IgPro20, the Polyneuropathy and Treatment with Hizentra
Berger M; Harbo T; Cornblath DR; Mielke O
Immunotherapy; 2018 Aug; 10(11):919-933. PubMed ID: 29764262
[TBL] [Abstract][Full Text] [Related]
20. Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study.
RMC Trial Group
Lancet Neurol; 2009 Feb; 8(2):158-64. PubMed ID: 19136303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]